Introduction
Early identification of cognitive impairment in older adults is important given its prevalence. Successful aging incorporates normal cognitive function as a requirement for managing general activities of daily living. As longevity increases, so does the prevalence of cognitive problems. A national estimate of the prevalence of cognitive impairment of all types is available from the Aging, Demographics, and Memory Study (ADAMS) that estimates 14% of people older than 71 have cognitive impairment. 1 Research demonstrates that clinicians do not recognize or may not document suspicion of cognitive impairment in as many as 27-81% of their patients during routine visits. [2] [3] [4] A number of complex reasons may be in play to hamper clinicians' ability to recognize or document cognitive impairment, which may include discomfort with a discussion of findings of cognitive impairment, [2] [3] [4] uncertainty about the desire of a patient to explore cognitive problems, brief time for office visits, lack or systematic method of screening, concerns about the risk of misdiagnosis, and lack of experience with geriatric clients with cognitive impairment. 5 Some clinicians may believe that the impact of early diagnosis does not impact the individuals life sufficiently to warrant screening, or there are a lack of treatment options. 4, 5 For screening choices, clinicians are familiar with the Mini-Mental State Examination (MMSE) 3 and the Montreal Cognitive Assessment (MoCA), 6, 7 impractical for this brief appointment, and may not be aware of brief cognitive screens available for use.
The fifteen minute Annual Wellness Visit (AWV) was added as a new Medicare benefit with the passage of the Patient Protection and Affordable Health Care Act of 2010. The Centers for Medicare and Medicaid Services (CMS) requires detection of cognitive impairment in addition to a routine review of history, physiological assessment, list of medications and clinicians, and suggested preventative care (AWV). The CMS has not recommended a particular instrument for detection of cognitive impairment. The National Institute of Aging (NIA), The Gerontological Society of America (GSA), and the Alzheimer's Association formed task forces, and have published their recommendations for conducting a patient visit that includes recommendations for use of brief cognitive screens. 1, 8 The workgroups agreed that informal observation by the primary clinician was not sufficient to determine impairment.
The primary aim of the workgroups was to identify cognitive screens that can be administered in less than five minutes, are free of charge, have sound psychometric properties, and produce valid assessment data in Medicare populations. 8 To determine whether
The purpose of this article is to provide a review of five brief cognitive screens for potential use in the AWV. While lengthier, the MMSE and the Montreal Cognitive Assessment (MoCA) are also presented because each continue to be highly utilized in a variety of health care settings and are used as comparisons when brief cognitive screens are under consideration for adoption by clinicians. An additional purpose is to discuss how clinicians may incorporate brief cognitive screens into primary care visits and provide recommendations for choosing a suitable screen.
Method
A search of articles presenting brief cognitive screens were identified from databases (PubMed, CINHAL) using key terms brief cognitive screening, older adults, and cognitive impairment yielded over 200 results. The narrowing of the search by adding primary care yielded 33 results. In addition to the published articles by authors of the screens, the National Institute on Aging's (NIA's) searchable database of 116 screens for cognitive impairment was also useful to find brief cognitive screens meeting criteria appropriate for use in primary care. 10 Patient assessment instruments from the Alzheimer's toolkit were chosen for evaluation, as the workgroup had narrowed their search by evaluating systematic reviews of brief screens that met should include the principle components of a neurocognitive assessment. 2 Brief cognitive screens may address questions that both patients and caregivers may have about memory. Such screens capture patient-only, informant-only, or a combination of patient and informant data. Suitable screens (preferably less than 5 minutes) should be reliable and produce valid data. Each screen must have high sensitivity, meaning that it accurately identifies patients who have mild cognitive impairment as well as more advanced states of cognitive decline, and high specificity, meaning that it identifies patients who are not likely to have cognitive impairment. These screens should be low or no cost, easy to administer, acceptable to patients, and free from cultural, educational, and language biases. 2 In addition, brief screens should perform well against the widely used Mini-Mental State Examination.
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Meeting a number of these criteria above, the the s-MOCA, 12 Mini-Cog™, 13 the Memory Impairment Screen (MIS), 14 the General Practitioner Assessment of Cognition (GPCOG), 15 and the EightItem Interview to Differentiate Aging and Dementia (AD8) 16 are presented. The five screens can be administered by clinicians or allied health staff and have little or no language, educational, or cultural bias. All brief screens can be administered in 5 minutes or less and are equal or superior to the longer Mini-Mental State Exam (MMSE) 17 and MoCA 6,7 used for screening more select cognitive problems. The characteristics of each cognitive screen are described with psychometric properties, usefulness and limitations. A summary description of these screening instruments, including scoring properties, is included in Table 1 , and the instruments' psychometric properties are summarized in Table 2 .
Mini-mental state examination (MMSE): considered the "gold standard"
The Mini-Mental State Examination was developed for primary care clinicians in 1975. 17 While there were other, lengthier cognitive batteries available at that time, the MMSE was developed as a clinically appropriate and relatively brief screen to give a practical assessment of change in cognitive status in older adults. 6, 17 Not considered brief by today's standards, the screen includes 5 sections covering a wide range of diverse items: orientation, attention/ concentration, memory, language, and visuospatial ability. The MMSE is the most widely used screen available in multiple languages and therefore has a wide range of utility. Registration and purchase are required per the copyright, which may be prohibitive.
Psychometric properties
The MMSE has demonstrated reliability ranging from 0.31 to 0.96 depending on the setting and who administered the instrument. The MMSE was originally validated in a group of 206 subjects (r = 0.66-0.77) and over decades has continued to demonstrate moderate validity across different populations. 27 Sensitivity and specificity of the MMSE to determine cognitive impairment has ranged from 61% -91% and 86.2% -99%, respectively.
3,28
The MMSE may not be able to accurately distinguish normal cognitive function from mild impairment due to the influence of educational level and cultural biases, called the "ceiling effect." 6, 18, 28 • Considered the "Gold Standard," cited over 13 .000 times in the literature.
• Best value of MMSE was for ruling out dementia where negative predictive values were 98.5% and 95.7%, respectively 17 • Proprietary-must be purchased from www.parinc.com
• Ceiling effect means MCI may be missed in higher education levels.
• May not discriminate normal cognitive function from MCI.
• Educational and cultural biases.
• 10-minute administration
MoCA
• Internal consistency reliability α = .83
• Test-retest reliability collected on 26 participants, on average 35 days apart: r = 0.92 6
• Validated against the MMSE r = 0.87 6 • Widely used/ validated in 6 languages 0.57-0.90 At cut off score of 26 6, 8 75.9-0.97 at cut off score of 26 6, 8 • Recommended when patients fail a briefer screen. Good at differentiating normal cognition from MCI. 6 • Recommended that patients with no cognitive complaints receive MoCA, but may also be paired with items from MMSE for patients/informants with concerns about cognition 17 • • Informant only has lower specificity 2
• Mixed review as to whether GPCOG is free of educational bias 20 
MIS
Satisfactory alternate forms reliability (r = 69), high internal consistency/ reliability (α = .67) 10, 21 • • Better sensitivity than CDT alone 3 • Recommended for use in acute care to help with discrimination of cognitive impairment from normal cognition 23 https://www.youtube.com/ watch?v=Gb4WoOq3aA0
• Recommended as suited for use in AWV by Alzheimer's workgroup 2 • Researchers disagree on sensitivity for mild cognitive impairment 24 • Differences in scoring CDT could affect sensitivity 11 • Must have ability to draw and write.
AD8 • Internal Consistency
Cronbach's α = 0.84 25 • Good interrater reliability and stability (kappa = 0.67; 0.59 to 0.75) 26 Correlated Foreign culture or low reading levels as well as sensory impairments may also cause false positive screens. 18 The MMSE may be used by a wide range of clinicians, including nurses and social workers. However, the instrument takes 10 minutes to administer, and is too lengthy for the AWV. The MMSE demonstrates some cultural and educational biases, and is proprietary with a cost as high as $1 per use, so a briefer screen may be a better choice.
Montreal cognitive assessment (MoCA)
The Montreal Cognitive Assessment (MoCA) 7 was also originally developed as a brief screen for cognitive impairment, including mild cognitive impairment (MCI), and has been determined to be comparable in length and psychometric properties to the MMSE. 6 The MoCA is available for use in more than 12 languages.
The instrument includes six subscales covering a wide range of items: short-term memory, visuospatial, executive function, attention/concentration, language function, and orientation. The MoCA, a one-page pencil and paper screen, is available in the public domain and may be administered by non-physicians, with training highly recommended.
Psychometric properties
Test-retest reliability were collected at 35 ± 17.6 days apart with a resulting high correlation coefficient = 0.92, p < .001. Internal consistency reliability (Cronbach's α = 0.83) was established as good, validity was determined in a variety of psychometric studies, and the correlation between MoCA and the MMSE was deemed high (r = 0.87, P < .001). 6 The MoCA has been compared with the MMSE for sensitivity and specificity in several studies. The MoCA outperformed the MMSE in detecting MCI. 6 Both Stewart et al. and Markwick et al. noted that participants who tested within normal ranges on the MMSE had deficits identified by the MoCA. 19, 27 The MoCA can be used free of charge. If patients are concerned about cognitive decline but have no functional problems, the MoCA is a good choice, as it better distinguishes normal cognition from MCI. 6 However, the MoCA would be difficult to fit into the AWV due to the length of the screen (10-15 minutes), and the need for professional interpretation of the scores. The s-MoCA has psychometric properties similar to the MoCA, and is included as an alternate screen for the AWV. According to the MoCA website, training and certification will be required, although no date for this decision has yet been posted. The s-MoCA, developed by Roalf et al., reflects the standard MoCA, is psychometrically sound and can be administered in about 5 minutes. For these reasons, the s-MoCA was selected from the 3 for this review.
Roalf et al. used item response theory and computerized adaptive testing to develop the 8 items of the s-MoCA that have been tested in a community based clinic sample of 1,850 subjects with and without normal cognitive functioning. Items selected for the s-MoCA span several neurocognitive domains, a direct reflection of the standard MoCA. 12 Items are from the original 6 subscales measuring short-term memory, visuospatial, executive, attention/ concentration, language, and orientation. The instrument is available in the public domain and may be administered by any trained clinician.
Test-retest reliability was very good at (ICC = 0.89, p < 0.001). Scores on the s-MoCA were correlated with the standard MoCA (r = 0.95). Larner found the s-MoCA demonstrated acceptable sensitivity (0.63) and specificity (0.86) for the determination of cognitive impairment in two cohorts of patients in a memory clinic. 22 Roalf et al. assert that the s-MoCA is an improvement over versions developed by Horton et al. 20 and Wong et al. 21 because those studies were tested with a limited sample size and a narrow range of cognitive diagnoses. 12 As with the MoCA, the s-MoCA may be less sensitive with groups of patients who are less educated, which may limit generalizability. However, since the original MoCA has demonstrated sensitivity to early cognitive changes across domains, the shortened s-MoCA may be a good choice as a brief screen.
General practitioner assessment of cognition (GPCOG)
The GPCOG was developed as a brief informant screen for primary care from 3 other validated instruments. 15 The GPCOG includes both patient and informative screens. The patient version includes 6 cognitive items: an information statement for later recall, time orientation, two elements of clock drawing, a current events question, and a repeat of the recall item. The informant interview asks 6 questions about "how the patient is compared to when she/he was, say 5-10 years ago." The instrument is available in several languages in the public domain and may be administered by any trained clinician.
Psychometric properties
Tests of reliability included interrater, intraclass correlation (ICC) and test-retest, which ranged from 0.75-0.87. Internal consistency was strong (Cronbach's α = 0.75-0.84) for both patient and informant screens. The validity of the screen was assessed by comparison with the criterion standard of diagnoses of dementia. The GPCOG is most sensitive (0.82) and specific (0.83) for the combined patient and informant sections. Since the sensitivity and specificity are improved when using both the informant and patient interviews, another screen may be more suitable if there is no informant available. 15 The strengths of the instrument are similar to the MMSE when both the patient and informant tests are used. 15, 18, 29 The screen is simple to administer and score. The informant interview may be very helpful when a family member or caregiver has concerns about the patient's cognition. 2 There is no cost associated with instrument use, and the website provides a demonstration of use and scoring for the clinician. Cordell et al. determined that the GPCOG is relatively free from education or cultural biases, 2 but Lorentz et al. noted that one of the screens used to develop the GPCOG was biased by socioeconomic factors and urged caution when interpreting results. 29 
Memory impairment screen (MIS)
The MIS was developed for primary care as a verbally administered instrument for primary care and community settings. 2 The Memory Impairment Screen (MIS) was developed by Buschke et al. as a 4-minute, 4-item, delayed and cued-recall test of memory impairment. 30 This screen is described by the authors as using controlled learning to ensure attention, induce specific semantic processing to improve detection of cognitive impairment. Subjects are given the names of items and are told there are 4 different established categories (e.g., animal, city, vegetable, and game). 30 
Psychometric properties
Alternate forms reliability of the MIS was determined to be satisfactory (r = 0.69), and internal consistency/reliability is acceptable (Cronbach's a = 0.67). 14, 30 The MIS demonstrated high discriminative validity as a screening test when compared with a conventional 3-word recall, as is used in the MMSE. The sensitivity and specificity ranged from 0.80-0.99 for discriminating cognitive impairment versus normal cognition. 30 This instrument is publicly accessible and easy to use and score and it can either be self-administered or read to a patient, removing a literacy requirement. Designated as a good choice for the AWV by the Alzheimer's Association, 1,2 the test is acceptable to patients because the use of category cues improves attention and increases retrieval.
18,30 MIS performance is independent of age, depression scores, culture, and education. As an interview, it is also appropriate for those with motor impairments because there is no writing or drawing required.
Limitations for the MIS include having to be familiar with the word list options, which may introduce bias.
14 Since the MIS is primarily a test of memory, it does not test visuospatial skills or executive function, which may be important in determining daily function and decision-making. 2, 18, 24 Some disorders of the brain, like frontotemporal dementia, may have relatively intact memory, and patients with this type of cognitive impairment would be missed by use of the MIS. 31 This screen would not be a good choice for patients who have verbal impairments.
Mini-Cog
Borson et al. developed the Mini-Cog to assist with the discrimination of different cognitive changes. 13 The screen was also developed to improve upon the Clock Drawing Test (CDT), which as a single screen has limitations in sensitivity and predictive validity. The Mini-Cog is administered over 3 minutes and includes an assessment of the patient to recall 3 words and draw a clock. The patient is asked to repeat and remember three unrelated words from a choice of 6 validated 3-word lists and then complete the CDT before recalling the word list. 13 
Psychometric properties
Assessments of reliability are limited. In one Korean translation of the Mini-Cog, test-retest reliability was deemed "reasonable" over 4 weeks (r = 0.85, P < 0.01). 23 The Mini-Cog was validated against the MMSE in a random sample of community living older adults and found comparable, demonstrating a range of sensitivity from 76% -99% respectively and a specificity from 89% to 93% in predicting cognitive problems. 18, 25, 26, 32 The Mini-Cog is easily administered and relatively free from educational, language, and cultural biases, and psychometrically comparable to the MMSE. There is a free demonstration of the MiniCog through the John A. Hartford Institute of Geriatric Nursing "Try This" series. 23 Training for use of the Mini-Cog is optional, but a wide range of professionals can administer this instrument in about 3 minutes.
Limitations of the Mini-Cog include needing the physical and executive ability to hold a pen and draw a clock face. Borson et al. 13 refer to several studies that indicate there are differences in how the CDT may be administered and scored, which can affect the sensitivity of the test. There is disagreement among researchers as to the sensitivity of the Mini-Cog to detect mild cognitive impairment. 32 
Eight-item interview to differentiate aging and dementia (AD8)
Galvin et al. 16 developed the Eight-Item Interview to Differentiate Aging and Dementia (AD8) as a very brief informant interview for primary care. Galvin et al. preferred to interview an informant to identify individuals with mild cognitive problems. Such interviews have documented face validity and are well established in clinical research citing the Clinical Dementia Rating (CDR) and the Informant Questionnaire on Cognitive Decline (IQCODE) as evidence. 16 In 2007, the AD8 was validated as a direct assessment independently administered from an informant interview. 24 The assessment may be administered to the respondent and/ or the informant using pen and pencil or by direct oral question. Each question is answered "No" or "Yes, a change." Memory, orientation, judgment, and function questions assess any change in the ability of the patient to remember appointments, keep track of current events, express level of interest in hobbies, and balance a checkbook. The AD8 takes 3 minutes to administer, is available in the public domain, and does not require extensive training.
Psychometric properties
Tests of reliability were reported. Internal consistency yielded a Chronbach's α = 0.84. 33 Both in-person and phone administration demonstrated equal reliability (0.65), and interrater reliability was good (0.80). 34 The informant battery was validated against the CDR (2005). The AD8 correlated strongly with CDR scores (r = 0.75). Participants' AD8 scores had adequate agreement with informants' AD8 scores (intraclass correlation coefficient, 0.53; 95% CI, 0.41-0.62) and correlated with subjective complaints of memory problems (r = 0.47, P < .001). 24 Administered to the informant or the patient, the AD8 demonstrated sensitivity >84% and specificity >80%. 16 The advantages of this screen are its brevity and ease of administration, requiring no training. The informant and patient versions demonstrate similar strong psychometric properties, 24 so the examiner may administer the screen in the absence of an informant. Galvin did improved the AD8 by adding Word List Recall to the assessment, improving the predictive value of the assessment. 24 It is attractive for its practical application in that "remembering appointments" or "problems with daily thinking or memory" directly affect the lives of patients and caregivers. 16 With studies that have validated both informant and patient screens, either may be chosen. The clinician website includes a demonstration of use of the informant screen by telephone, which could increase the possibility of using both screens. The ability and willingness of the patient or the availability of an informant may limit the choice of the screen.
Discussion

Choosing a brief cognitive screen
The brief screening assessments presented in this article were chosen for their practicality, availability, psychometric properties, and acceptance by clinicians and patients. Screens included the principle components of a neurocognitive assessment: attention, memory, language, visuospatial skills, and executive function. 9 The screens presented here have training options available from either the Cognitive Assessment Toolkit by the Alzheimer's Association or training websites.
With the exception of the MMSE (a longer screen), all others are free of charge. The decision on a brief screen should be based upon a) clinician preference b) the availability of an informant (yes/no), and c) patient characteristics such as ability to write or draw. No one screen will fit every situation. For example, clinicians familiar with the MoCA might prefer the s-MoCA. Other clinicians may prefer screens with both patient and informant versions, like the AD8 or the GPCOG. Both patient and informant versions could be administered by paper and pencil prior to the actual AWV appointment time, comfortably performed by a trained allied health professional in a private office, allowing for more time for clinician followup during the AWV. 18 Both the AD8 and the GPCOG had satisfactory psychometrics when compared with the MMSE 15, 33 Informant screens may also be helpful when patients have low educational levels or are otherwise challenged to respond to screening. 28 
Implementing brief cognitive screens
Nurses and nurse practitioners, often first points of contact for patients, are important partners to families and other professionals as early identifiers of patient cognitive impairment. Early diagnosis can lead to better health outcomes whether the cause of the impairment is dementia or other issues such as low vitamin B12 or hypothyroidism. [2] [3] [4] However, some patients may not choose to participate in a cognitive screen regardless of the cause, and the desire to know about cognitive impairment should be a choice by the patient. 4, 5 The diagnosis of dementia can be both frightening and depressing, and both providers and patients may feel limited in the approaches with medication. Recent research evidence suggests that non-pharmacological approaches to dementia care are important for emotional and functional support, and perhaps earlier provision of resources with identification of cognitive problems could be helpful, and are part of the role of the nurse and nurse practitioner. 4, 5 After choosing and administering a brief cognitive screen, nurses should have mechanisms in place to refer patients for further evaluation if needed. Screens of any type are actually designed to rule out symptoms. If the nurse is not able to rule out cognitive impairment with a brief screen, then follow up is warranted. In some cases, referrals can be made to primary care MDs, and in other cases it may be necessary to refer patients to a neurology department or possibly a research center for a more in depth exam and testing.
Some patients and families will want to know the results of the cognitive screening, as well as the trajectory over the years. Some may ask for genetic testing. Office policies and procedures should be in place to guide all of the clinicians on these issues. Additionally, everyone administering cognitive screens needs training to maintain the reliability of the scores between clinicians and across years.
Some patients will ultimately receive a medical diagnosis of Alzheimer's disease or a related dementia. In these cases, nurses will participate to strategize long-range plans with patients and caregivers. 8 Patient and family reporting of symptoms and problematic behaviors should be interpreted based on the level of impairment, other coexisting conditions, and numbers and types of patient medications. 8 Cognitive screening during the AWV is important. The process can identify cognitive problems early in the course of an illness, whether caused by dementia or other medical conditions. If cognitive impairment remains unidentified then medical conditions remain untreated. For those patients with dementia, communitybased supports, education, and caregiver resources remain out of reach for them and caregivers.
The Gerontological Society of America (GSA) workgroup suggests a 4-step process to address the detection of cognitive impairment in the AWV that may be useful 8 
:
Step 1: Kickstart the cognition conversation,
Step 2: Assess if symptomatic,
Step 3: Evaluate with a brief cognitive screen or a full diagnostic, and Step 4: Refer to community resources and clinical trials, depending on the diagnosis.
Steps 1 & 2 encourage the clinician to begin the conversation with patients and their families about memory issues that may be surfacing. In addition to memory problems that are uncovered, the clinician should be aware of other risk factors mentioned (fall risk, medication side-effects, depression). The use of a brief cognitive screen is included as part of Step 2, the assessment.
The third step, a full cognitive evaluation, requires processes in place for a referral to a specialist in order to obtain a diagnostic workup. The primary clinician group must work together to have these processes in place so that once the level of impairment is ascertained, the appropriate resources and community supports may be initiated. The early diagnosis of cognitive problems due to such neuro degenerative conditions as dementia, allows the patient and family to have conversations about what is important for future care and advance directives and to plan for legal and financial matters. "Kickstarting" the conversation in the primary care setting could result in avoiding crisis situations later and in improved health outcomes. 8 
Conclusion
The Alzheimer's Association and Gerontological Society of America (GSA) workgroups have recommended that clinicians in primary care incorporate brief cognitive screens into the Annual Wellness Visit (AWV). This article highlights the findings of the workgroups in a review and critique of psychometrically sound, brief cognitive screens that are feasible to use during the AWV. Not all patients will choose to participate in cognitive screening, however the benefits of early screening include the discovery of problems with cognition that can affect daily function, provision of early interventions for patients and families, and referral of patients who will need further evaluation. A reliable brief cognitive screen that generates valid assessment data can provide a routine measure considered part of the overall assessment of patient wellness in the Annual Wellness Visit.
